H1N1 News and Research RSS Feed - H1N1 News and Research Twitter

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
New study affirms value of influenza vaccination among older people

New study affirms value of influenza vaccination among older people

A new study of the records of millions of nursing home residents affirms the value of influenza vaccination among the elderly. The Brown University analysis found that between 2000 and 2009, the better matched the vaccine was for the influenza strain going around, the fewer nursing home residents died or were hospitalized. [More]
TSRI, Janssen collaborate to find universal flu vaccine

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
Regenstrief to highlight open source options for health information exchange, data analysis at MedInfo 2015

Regenstrief to highlight open source options for health information exchange, data analysis at MedInfo 2015

Regenstrief Institute investigators experienced in the use of data to improve health care and its delivery in resource constrained environments will introduce attendees at MedInfo 2015 to open source options for health information exchange and data analysis. [More]
Social and environmental processes linked to 2009 H1N1 pandemic outbreaks in Mexico

Social and environmental processes linked to 2009 H1N1 pandemic outbreaks in Mexico

Scientists studying the 2009 A/H1N1 influenza pandemic have found that the inconsistent regional timing of pandemic waves in Mexico was the result of interactions between school breaks and regional variations in humidity. [More]
H1N1 vaccine developed at UNMC to be evaluated in animal study

H1N1 vaccine developed at UNMC to be evaluated in animal study

An H1N1 vaccine developed at the University of Nebraska Medical Center will enter a definitive round of testing this month, and researchers hope to establish its ability to ward off the virus. [More]
NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program. [More]
Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC. [More]
Commission on Global Health Risk Framework for the Future holds first public meeting

Commission on Global Health Risk Framework for the Future holds first public meeting

Over the past 15 years, outbreaks of Ebola, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and H1N1 have demonstrated the lack of an adequate local and global health system infrastructure to prevent or mitigate the systemic burdens that result from infectious disease incidents of international significance. [More]
New mathematical simulation model helps manage ICU bed occupancy effectively

New mathematical simulation model helps manage ICU bed occupancy effectively

The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre. [More]
GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to US healthcare providers, following licensing and lot-release approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research. [More]
New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful. [More]
Creating more effective vaccines against flu virus

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. [More]
Analysis of transportation data could help predict spread of flu epidemic across the U.S.

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

To predict how a seasonal influenza epidemic will spread across the United States, one should focus more on the mobility of people than on their geographic proximity, a new study suggests. [More]
Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression. [More]
NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market. [More]
NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection. [More]
Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics, today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs. [More]
Simple, effective portable tool can help predict avian flu outbreaks

Simple, effective portable tool can help predict avian flu outbreaks

A simple and effective portable tool to predict avian flu outbreaks on farms has been created by University of Guelph researchers. [More]
UofL-led study focuses on flu vaccine for children with neurological disorders

UofL-led study focuses on flu vaccine for children with neurological disorders

Children who have neurological disorders such as cerebral palsy or epilepsy are no more likely to be vaccinated against influenza than youngsters without these conditions, despite the increased risk for complications from flu these children experience. [More]
Advertisement
Advertisement